Cancer treatment firm Sirtex Medical is highlighting clinical results from its colorectal cancer trial published online in the Journal of Clinical Oncology.
The SIRFLOX clinical study was conducted by lead investigator Dr. Guy van Hazel of the University of Western Australia in West Perth and colleagues. Between October 2006 and April 2013, 530 patients were randomly assigned to one of two treatment groups: a control group that underwent standard chemotherapy and a second group that underwent selective internal radiation therapy using yttrium-90 resin microspheres and chemotherapy (JCO, February 22, 2016).
The study found that although its SIR-Spheres yttrium-90 (Y-90) resin microspheres did not yield a statistically significant improvement in overall progression-free survival for treating nonresectable metastatic colorectal cancer, there was a statistically significant improvement in progression-free survival in the liver, according to the firm.
